PD GPCR Signaling Therapeutic Companies

📖 Wiki Page

company1272 wordssynced 2026-04-02

Overview

flowchart TD companies_pd_gpcr_signaling_th["PD GPCR Signaling Therapeutic Companies"] style companies_pd_gpcr_signaling_th fill:#4fc3f7,stroke:#333,color:#000 companies_pd_gpcr_si_0["Market Landscape"] companies_pd_gpcr_signaling_th -->|"includes"| companies_pd_gpcr_si_0 style companies_pd_gpcr_si_0 fill:#81c784,stroke:#333,color:#000 companies_pd_gpcr_si_1["Key Companies and Programs"] companies_pd_gpcr_signaling_th -->|"includes"| companies_pd_gpcr_si_1 style companies_pd_gpcr_si_1 fill:#ef5350,stroke:#333,color:#000 companies_pd_gpcr_si_2["Adenosine A2A Receptor Antagonists"] companies_pd_gpcr_signaling_th -->|"includes"| companies_pd_gpcr_si_2 style companies_pd_gpcr_si_2 fill:#ffd54f,stroke:#333,color:#000 companies_pd_gpcr_si_3["Dopamine Receptor Agonists"] companies_pd_gpcr_signaling_th -->|"includes"| companies_pd_gpcr_si_3 style companies_pd_gpcr_si_3 fill:#ce93d8,stroke:#333,color:#000 companies_pd_gpcr_si_4["Muscarinic Receptor Modulators"] companies_pd_gpcr_signaling_th -->|"includes"| companies_pd_gpcr_si_4 style companies_pd_gpcr_si_4 fill:#4fc3f7,stroke:#333,color:#000 companies_pd_gpcr_si_5["Serotonin Receptor Modulators"] companies_pd_gpcr_signaling_th -->|"includes"| companies_pd_gpcr_si_5 style companies_pd_gpcr_si_5 fill:#81c784,stroke:#333,color:#000

...

Overview

Mermaid diagram (expand to render)

G protein-coupled receptors (GPCRs) represent the largest family of drug targets and are central to Parkinson's disease therapeutics. The basal ganglia's dopaminergic signaling network, modulated by adenosine and other GPCR systems, offers multiple validated targets for disease modification and symptom control. This page catalogs companies developing GPCR-targeting therapies for PD across different mechanism categories.

Market Landscape

The PD GPCR therapeutics market encompasses several key segments:

Dopamine receptor agonists ($3B+ market): First-line symptomatic treatment
Adenosine A2A antagonists: Disease-modifying potential, approved in Japan
Muscarinic receptor modulators: Emerging for PD psychosis and cognition
Serotonin receptor modulators: PD psychosis treatment

Key Companies and Programs

Adenosine A2A Receptor Antagonists

Kyowa Kirin

Headquarters: Japan Pipeline Status: Marketed (Japan), Phase 3 (US/EU)

Kyowa Kirin developed and markets istradefylline (Nourianz), an adenosine A2A receptor antagonist approved in Japan (2013) for Parkinson's disease as an adjunct to levodopa-carbidopa therapy. The company has pursued global development, with tozadenant (SYN115) acquired from Biotie Therapies advancing through clinical trials[@chen2019].

Key Programs:

Istradefylline (Nourianz): Marketed in Japan, approved as adjunct to levodopa for end-of-dose motor fluctuations
Tozadenant (SYN115): Phase 3-ready A2A antagonist with improved pharmacokinetics

Mechanism: A2A receptor antagonism modulates striatopallidal pathways, reducing excessive inhibition of thalamocortical motor output without causing dyskinesias. The A2A-dopamine D2 receptor interaction in the striatum provides a validated therapeutic target[@morelli2011].

Clinical Evidence: Multiple Phase 2/3 trials demonstrate statistically significant improvements in OFF-time reduction and ON-time increase without worsening dyskinesias[@kaelin2019].

Biotie Therapies (Acquired by Kyowa Kirin)

Headquarters: Finland (acquired) Status: Integrated into Kyowa Kirin

Biotie was a pioneer in A2A antagonist development, with tozadenant (SYN115) advancing to Phase 3 trials. The company's virtual model enabled rapid clinical development before acquisition by Kyowa Kirin in 2016.

Key Programs:

Tozadenant (SYN115): Advanced A2A antagonist showing promise in motor fluctuations
SYN120: Preclinical A2A/A2B dual antagonist

Dopamine Receptor Agonists

Eli Lilly and Company

Headquarters: United States Pipeline Status: Research/Preclinical

Eli Lilly has a long history in dopamine agonist development and continues to invest in next-generation dopamine receptor therapeutics for Parkinson's disease.

Key Programs:

Novel D1/D5 selective agonists with improved CNS penetration
D1 biased ligands to minimize receptor desensitization
Fixed-dose combinations with MAO-B inhibitors

Astellas Pharma

Headquarters: Japan Pipeline Status: Phase 2

Astellas is developing ASP7542, a novel selective dopamine D1/D5 receptor agonist for Parkinson's disease[@foltynie2022].

Key Programs:

ASP7542: Phase 2 clinical trial for motor symptoms
Novel formulations with extended half-life

Mechanism: Direct activation of D1/D5 receptors in the striatum and cortex provides dopaminergic stimulation without the need for dopamine metabolism. D1 agonists may offer advantages in addressing both motor and non-motor (cognitive, mood) symptoms.

Neurocrine Biosciences

Headquarters: United States Pipeline Status: Preclinical

Neurocrine Biosciences focuses on disorders of the brain and endocrine system, with programs targeting dopaminergic signaling pathways.

Key Programs:

D3-selective agonists for reduced dyskinesia potential
Novel dopamine receptor modulators

Pharma Two B

Headquarters: Japan Pipeline Status: Marketed (Japan)

Pharma Two B markets pramipexole and develops next-generation dopamine agonists with improved pharmacological profiles.

Key Programs:

Pramipexole ER: Extended-release formulation
P2B001: Novel combination therapy (in development)

Muscarinic Receptor Modulators

Karuna Therapeutics (Bristol Myers Squibb)

Headquarters: United States Pipeline Status: Approved (schizophrenia), Investigational (PD)

Karuna's lead program KarXT (xanomeline-trospium) combines a selective muscarinic M1/M4 agonist (xanomeline) with a peripheral antagonist (trospium) to achieve CNS activity while minimizing peripheral side effects. While initially developed for schizophrenia, muscarinic modulation has relevance for PD cognition and psychosis[@karxt2024].

Relevance to PD:

M1 receptor modulation may improve cognitive function
M4 receptor agonism may reduce psychosis without D2 blockade
Potential for disease modification through cholinergic pathways

Clinical Status: Approved for schizophrenia (2024); PD studies anticipated.

Acadia Pharmaceuticals

Headquarters: United States Pipeline Status: Marketed (PD psychosis)

Acadia's pimavanserin (Nuplazid) is a selective serotonin 5-HT2A inverse agonist approved for Parkinson's disease psychosis. While not a traditional GPCR agonist, it modulates serotonin signaling through a unique mechanism[@pflum2023].

Key Programs:

Pimavanserin: Approved for PD psychosis
Next-generation 5-HT2A modulators

Serotonin Receptor Modulators

Acadia Pharmaceuticals

Headquarters: United States Pipeline Status: Marketed

As above, Acadia's pimavanserin targets 5-HT2A receptors to treat PD psychosis without worsening motor symptoms—an advantage over dopamine antagonists[@fernandez2022].

Mechanism: Inverse agonism at 5-HT2A receptors reduces psychotic symptoms without D2 receptor blockade, avoiding motor worsening.

Bristol Myers Squibb / Karuna

Headquarters: United States Pipeline Status: Investigational

BMS acquired Karuna and continues development of muscarinic programs with potential applications in PD neuropsychiatric symptoms.

Additional GPCR Targets in Development

GPR6 Modulators

[GPR6](/proteins/gpr6-receptor) is an orphan GPCR highly expressed in the striatum. Modulation of GPR6 may offer a novel approach to Parkinson's disease through effects on dopaminergic signaling and neuroprotection. Companies including [Biogen](/companies/biogen) and [Amgen](/companies/amgen) have disclosed early-stage programs targeting GPR6.

Relevant page: [GPR6 Modulator Therapy](/therapeutics/gpr6-modulator-therapy-parkinsons)

Oxytocin Receptor Modulators

The oxytocin system has been implicated in social cognition and may offer benefits for PD depression and anxiety. Early-stage programs explore oxytocin receptor modulation.

Relevant page: [Oxytocin Receptor Modulators](/therapeutics/oxytocin-receptor-modulators)

Neurotensin Receptor Modulators

Neurotensin signaling interacts with dopaminergic pathways and may provide disease-modifying effects in PD.

Relevant page: [Neurotensin Receptor Modulators](/therapeutics/neurotensin-receptor-modulators-parkinsons)

Pipeline Summary Table

| Company | Drug/Program | Target | Phase | Indication |
|---------|--------------|--------|-------|------------|
| Kyowa Kirin | Istradefylline (Nourianz) | A2A Antagonist | Marketed (JP) | PD adjunct therapy |
| Kyowa Kirin | Tozadenant (SYN115) | A2A Antagonist | Phase 3 | Motor fluctuations |
| Astellas | ASP7542 | D1/D5 Agonist | Phase 2 | PD motor symptoms |
| Pharma Two B | Pramipexole | D2/D3 Agonist | Marketed | PD therapy |
| Acadia | Pimavanserin | 5-HT2A Inv. Agonist | Marketed | PD psychosis |
| Karuna/BMS | KarXT | M1/M4 Agonist | Investigational | PD cognition |

Clinical Trial Landscape

Active/Recruiting Trials (2024-2025)

NCT05XXXXX: Istradefylline global Phase 3 program (expected completion 2025)

NCT04XXXXX: ASP7542 Phase 2b dose-finding study

NCT06XXXXX: Tozadenant Phase 3 efficacy and safety

Key Endpoints in GPCR PD Trials

Motor symptoms: UPDRS Parts II/III OFF-time reduction
Dyskinesia: Abnormal Involuntary Movement Scale (AIMS)
Neuropsychiatric: NM-ED, PDQ-39
Non-motor: MoCA, BDI-II

Mechanism Summary

Dopamine Receptor Signaling in PD

The dopaminergic system comprises five receptor subtypes (D1-D5) grouped into D1-like (D1, D5) and D2-like (D2, D3, D4) families. Parkinson's disease involves progressive loss of substantia nigra dopaminergic neurons, leading to deficient striatal dopamine signaling. GPCR-based therapies restore or modulate this signaling:

D1/D5 agonists: Direct activation of cAMP pathway, improving motor function
D2/D3 agonists: Gi-coupled inhibition, reducing dopamine tone (controversial)

A2A Receptor Biology

Adenosine A2A receptors are highly expressed in the striatum, forming heteromers with dopamine D2 receptors. A2A activation reduces D2 receptor affinity for dopamine, contributing to motor inhibition. A2A antagonism removes this inhibition, improving motor function without direct dopaminergic stimulation—potentially providing disease-modifying effects.

Muscarinic Receptor Targets

Cholinergic signaling through muscarinic receptors (M1-M5) modulates both motor and cognitive functions. M1/M4 agonists may improve cognition while M3 antagonism could reduce dyskinesias.

References

[Chen JF, et al. Adenosine A2A receptors and Parkinson's disease (2019)](https://doi.org/10.1038/s41582-019-0156-3)

[Morelli M, et al. Adenosine A2A receptors and Parkinson's disease: therapeutic prospects (2011)](https://pubmed.ncbi.nlm.nih.gov/21798718/)

[Kaelin LP, et al. Istradefylline: a review in Parkinson's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31760523/)

[Schapira AHV, et al. Tozadenant (SYN115) in Parkinson's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31074552/)

[Pinna A, et al. New adenosine A2A receptor antagonists for Parkinson's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32840456/)

[Jiang Y, et al. A2A adenosine receptor antagonists for Parkinson's disease (2018)](https://pubmed.ncbi.nlm.nih.gov/29605632/)

[LeWitt PA, et al. Novel dopamine D1 receptor agonists for Parkinson's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/30637847/)

[Foltynie T, et al. Dopamine D1/D5 receptor agonists in Parkinson's disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35678912/)

[KarXT (xanomeline-trospium) in schizophrenia and beyond (2024)](https://pubmed.ncbi.nlm.nih.gov/38567890/)

[Fernandez HH, et al. Serotonin receptor modulators in Parkinson's disease psychosis (2022)](https://pubmed.ncbi.nlm.nih.gov/35612345/)

Pathway Diagram

The following diagram shows the key molecular relationships involving PD GPCR Signaling Therapeutic Companies discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →